IL6 and metabolic syndrome: The associations between the subgroup of patients grouped by PaO2/FiO2 ratio and the administration of IL-6 blocker treatment (p = 0.04, Chi-squared test) metabolic syndrome (p = 0.03, Chi-squared test) were statistically significant.